Iqbal S Grewal

US Patent:

7419799, Sep 2, 2008

Filed:

Apr 29, 2002

Appl. No.:

10/136574

Inventors:

Patricia A. Valdez - San Francisco CA, US
Austin L. Gurney - Belmont CA, US
Iqbal Grewal - Fremont CA, US

Assignee:

Genetech, Inc. - South San Francisco CA

International Classification:

C07H 21/04
A61K 39/00
C12P 21/06
C12N 15/00
C12N 1/00
C12N 1/20
C12N 5/06
C07K 1/00

US Classification:

435 691, 536 235, 4241851, 4353201, 43525233, 4352542, 435358, 530350

Abstract:

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.

US Patent:

20020197256, Dec 26, 2002

Filed:

Mar 14, 2002

Appl. No.:

10/099818

Inventors:

Iqbal Grewal - Fremont CA, US

Assignee:

GENENTECH, INC.

International Classification:

A61K039/395

US Classification:

424/144100, 424/155100

Abstract:

The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a second agent which causes the depletion of cells expressing the CD20 membrane antigen. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.

US Patent:

20040234522, Nov 25, 2004

Filed:

Sep 15, 2003

Appl. No.:

10/663158

Inventors:

Frederic DeSauvage - Foster City CA, US
Iqbal Grewal - Redwood City CA, US
Austin Gurney - Belmont CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K039/395
A61K048/00

US Classification:

424/144100, 514/044000

Abstract:

The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.

US Patent:

20050031583, Feb 10, 2005

Filed:

Feb 6, 2002

Appl. No.:

10/129595

Inventors:

Iqbal Grewal - Fremont CA, US

International Classification:

A61K038/20
C12N005/08

US Classification:

424085200, 435372000

Abstract:

Methods of stimulating or inhibiting activity of monocytes using OPG ligand, or other agonists or antagonists, are provided. Methods of treating pathological conditions, particularly immune related conditions, using such OPG ligand, agonists or antagonists are further provided. Agonists and antagonists contemplated for use in the invention include anti-RANK receptor antibodies, anti-OPG ligand antibodies, anti-OPG receptor antibodies, RANK receptor immunoadhesins, and OPG receptor immunoadhesins.

US Patent:

20050043516, Feb 24, 2005

Filed:

Jul 25, 2003

Appl. No.:

10/626914

Inventors:

Anan Chuntharapai - Colma CA, US
Iqbal Grewal - Fremont CA, US
Kyung Kim - Cupertino CA, US
Minhong Yan - Burlingame CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K016/00
C12P021/08

US Classification:

530387900

Abstract:

TACI receptor antibodies are provided. The TACI antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the TACI antibodies are also provided.

US Patent:

20050070689, Mar 31, 2005

Filed:

Jul 24, 2002

Appl. No.:

10/485489

Inventors:

Vishva Dixit - Los Altos CA, US
Iqbal Grewal - Fremont CA, US
John Ridgway - San Francisco CA, US
Minhong Yan - Burlingame CA, US

Assignee:

GENENTECH, INC. - South San Francisco CA

International Classification:

C07K014/705
C07H021/04
C12N001/18
C12N005/06
C12N015/74

US Classification:

530350000, 536023500, 435069100, 435252330, 435254200, 435358000, 435320100, 435006000

Abstract:

Novel, receptors, referred to herein as “TACIs” and “BR3”, agonists and antagonists thereof, and method of using TACIs and BR3, as well as agonists and antagonists thereof, to modulate, for example, activity of tumor necrosis factor (TNF) and TNFR-related molecules, including members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA, are provided. Methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with such TNF and TNFR-related molecules are further provided.

US Patent:

20050271658, Dec 8, 2005

Filed:

May 3, 2005

Appl. No.:

11/120338

Inventors:

Paul Brunetta - San Francisco CA, US
Iqbal Grewal - Mill Creek WA, US
Patricia Walicke - Brisbane CA, US

International Classification:

A61K039/395

US Classification:

424144100

Abstract:

The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of the autoimmune disease.

US Patent:

20060073146, Apr 6, 2006

Filed:

Feb 28, 2005

Appl. No.:

11/069473

Inventors:

Avi Ashkenazi - San Mateo CA, US
Kelly Dodge - San Mateo CA, US
Iqbal Grewal - Fremont CA, US
Kyung Kim - Los Altos CA, US
Scot Marsters - San Carlos CA, US
Robert Pitti - El Cerrito CA, US
Minhong Yan - Burlingame CA, US

International Classification:

A61K 39/395
A61K 38/17

US Classification:

424144100, 514012000

Abstract:

Methods of using one or more agonists or antagonists to modulate activity of the members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA are provided. The methods include in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with TALL-1, APRIL, TACI, or BCMA, using one or more agonist or antagonist molecules. The methods of treatment disclosed by the invention include methods of treating immune related diseases and cancer.